Skip to main content
Graphic with text stating explore the chart to see how MenQuadfi aligns with the ACIP immunization schedule

ACIP Schedule

This example ACIP schedule demonstrates how MenQuadfi and stand alone MenB can be an option to complete the ACIP recommendations.3

An ACIP schedule chart showing MenQuadfi at ages 11–12 & 16 and MenB Monovalent at 16–18 years, with or without the pentavalent option

MENQUADFI IS AN OPTION TO COMPLETE THE ROUTINELY RECOMMENDED SCHEDULE

  • MenACWY should be administered routinely at 11-12 and 16 years of age3
  • MenB is optional through SCDM rather than routinely recommended3
  • MenQuadfi comes in a ready-to-use presentation that does not require reconstitution1
      

MENQUADFI AND A MONOVALENT MENB VACCINE EFFECTIVELY FULFILL YOUR IMD IMMUNIZATION NEEDS

  • MenQuadfi and MenB vaccines are fully liquid—no reconstitution required1
  • MenB is not routinely recommended in the ACIP vaccination schedule, so stocking both vaccines separately gives you flexibility for MenB vaccination when it’s needed1

IMD=invasive meningococcal disease.
  

A PENTAVALENT IS AN OPTION WHEN MenACWY AND MenB ARE TO BE GIVEN AT THE SAME VISIT

  • Follow-up visits to administer the second dose of MenB are needed 6 months after the pentavalent is administered3
  • Because some patients only need a MenACWY vaccine based on the ACIP guidelines, you may still need to stock a quadrivalent vaccine
      

Important Safety Information

MenQuadfi should not be administered to anyone who has had a severe allergic reaction to any component of the vaccine, or after a previous dose of MenQuadfi or any other tetanus toxoid-containing vaccine.

Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of MenQuadfi.

Some individuals with altered immunocompetence, including some receiving immunosuppressant therapy, may have reduced immune responses to MenQuadfi. Persons with certain complement deficiencies and those receiving treatment that inhibits terminal complement activation (eg, eculizumab) are at increased risk for invasive disease caused by N meningitidis, including serogroups A, C, W, and Y, even if they develop antibodies following vaccination with MenQuadfi.

Syncope (fainting) may occur in association with administration of injectable vaccines, including MenQuadfi. Procedures should be in place to avoid injury from fainting.

Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of another US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision to give MenQuadfi to persons with a history of GBS should take into account the expected benefits and potential risks.

Immunization with MenQuadfi does not substitute for routine tetanus immunization.

Vaccination with MenQuadfi may not protect all vaccine recipients.

The most common adverse reactions following primary vaccination with MenQuadfi in infants 6 weeks through 23 months of age include tenderness, erythema, and swelling at the injection site; irritability, abnormal crying, drowsiness, appetite loss, fever, and vomiting. In individuals 2 years of age and older, the most common adverse reactions include pain at the injection site; myalgia, headache, and malaise. Other common adverse reactions in children 2 through 9 years of age include erythema and swelling at the injection site. In adolescents and adults, rates of solicited adverse reactions following a booster dose were comparable to those observed following primary vaccination. Other adverse reactions may occur.

Please see the full Prescribing Information for MenQuadfi.

Learn more about Sanofi's commitment to fighting counterfeit drugs.

Important Safety Information

ACIP = Advisory Committee on Immunization Practices; MenABCWY = N meningitidis serogroups A, B, C, W, and Y; MenACWY = N meningitidis serogroups A, C, W, and Y; MenB = meningitis B; SCDM = shared clinical decision making.

MenQuadfi is a registered trademark of Sanofi.

REFERENCES:
1. MenQuadfi [Prescribing Information]. Sanofi.
2. Collins J; ACIP Meningococcal Vaccines Work Group. National Center for Immunization and Respiratory Diseases. Centers for Disease Control and Prevention. Summary of EtR and proposed recommendations for Pfizer’s MenABCWY vaccine. October 25, 2023. Accessed June 26, 2025. https://stacks.cdc.gov/view/cdc/134696
3. Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69(9):1-41.

MAT-US-2007152-v12.0-11/2025

Back to top
Back to top
SitemapLegal NoticePrivacy PolicyCookie PolicyDo Not Sell or Share My Personal InformationContact
© 2025 Sanofi. All rights reserved.